Free Trial

STERIS (STE) Competitors

STERIS logo
$241.64 -1.02 (-0.42%)
As of 09:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

STE vs. BDX, EW, IDXX, RMD, DXCM, PODD, BAX, HOLX, MASI, and GMED

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Masimo (MASI), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.

STERIS vs. Its Competitors

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, Becton, Dickinson and Company had 21 more articles in the media than STERIS. MarketBeat recorded 32 mentions for Becton, Dickinson and Company and 11 mentions for STERIS. STERIS's average media sentiment score of 1.23 beat Becton, Dickinson and Company's score of 0.89 indicating that STERIS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
20 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
STERIS
9 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Becton, Dickinson and Company currently has a consensus price target of $219.22, indicating a potential upside of 23.58%. STERIS has a consensus price target of $263.83, indicating a potential upside of 9.18%. Given Becton, Dickinson and Company's higher possible upside, research analysts clearly believe Becton, Dickinson and Company is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
0 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.36
STERIS
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.63

STERIS has a net margin of 11.26% compared to Becton, Dickinson and Company's net margin of 7.28%. Becton, Dickinson and Company's return on equity of 15.99% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company7.28% 15.99% 7.36%
STERIS 11.26%14.21%9.13%

Becton, Dickinson and Company has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$20.18B2.52$1.71B$5.2433.85
STERIS$5.46B4.35$614.64M$6.2038.97

Becton, Dickinson and Company pays an annual dividend of $4.16 per share and has a dividend yield of 2.3%. STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 0.9%. Becton, Dickinson and Company pays out 79.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 36.8% of its earnings in the form of a dividend. Becton, Dickinson and Company has increased its dividend for 53 consecutive years and STERIS has increased its dividend for 20 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

STERIS beats Becton, Dickinson and Company on 12 of the 19 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$23.75B$6.78B$5.48B$20.43B
Dividend Yield0.95%1.04%5.38%3.76%
P/E Ratio38.9527.0626.2227.62
Price / Sales4.3585.89394.9236.40
Price / Cash16.8521.0536.4921.79
Price / Book3.594.707.914.52
Net Income$614.64M$173.18M$3.15B$984.47M
7 Day Performance0.49%0.20%0.75%2.61%
1 Month Performance-0.10%-1.11%3.46%4.99%
1 Year Performance10.67%24.36%34.60%13.53%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.7155 of 5 stars
$241.64
-0.4%
$263.83
+9.2%
+10.9%$23.75B$5.46B38.9517,787Positive News
BDX
Becton, Dickinson and Company
4.7582 of 5 stars
$169.72
+0.8%
$219.22
+29.2%
-22.5%$48.64B$20.18B32.3974,000
EW
Edwards Lifesciences
4.3373 of 5 stars
$75.33
+2.0%
$80.20
+6.5%
-14.4%$44.19B$5.44B10.7615,800Positive News
IDXX
IDEXX Laboratories
3.7122 of 5 stars
$524.65
+0.1%
$546.00
+4.1%
+13.9%$42.19B$3.90B48.4911,000Positive News
Analyst Forecast
RMD
ResMed
4.6389 of 5 stars
$254.25
+0.2%
$259.33
+2.0%
+37.1%$37.28B$4.69B28.549,980News Coverage
Positive News
DXCM
DexCom
4.8968 of 5 stars
$79.84
-0.2%
$98.50
+23.4%
-25.5%$31.31B$4.03B59.5810,300Positive News
Analyst Downgrade
Insider Trade
Gap Down
PODD
Insulet
4.2164 of 5 stars
$307.67
+1.5%
$321.00
+4.3%
+52.9%$21.65B$2.07B55.343,900Positive News
BAX
Baxter International
4.1443 of 5 stars
$30.01
+0.1%
$37.25
+24.1%
-5.5%$15.40B$10.64B-27.2838,000
HOLX
Hologic
4.7472 of 5 stars
$64.43
-0.1%
$77.42
+20.2%
-11.8%$14.36B$4.03B27.197,063Positive News
MASI
Masimo
4.3233 of 5 stars
$168.12
+1.8%
$191.60
+14.0%
+45.2%$9.12B$2.09B-18.335,600
GMED
Globus Medical
4.9609 of 5 stars
$57.82
-0.1%
$94.00
+62.6%
-11.5%$7.83B$2.52B43.155,300Positive News
Analyst Revision

Related Companies and Tools


This page (NYSE:STE) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners